Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Karuna Pharmaceuticals
Biotech
BMS beat 2 other pharmas in bid for RayzeBio
Bristol Myers Squibb's $4.1 billion bid for RayzeBio was enough to beat out two other companies that also put down offers.
Gabrielle Masson
Jan 25, 2024 1:35pm
Karuna hits goal in schizophrenia phase 3, teeing up 2023 filing
Aug 8, 2022 9:48am
As Russia prepared for war, Karuna's team prepped patients
Mar 3, 2022 11:00am
Cerevel stock doubles on success of phase 1b schizophrenia trial
Jun 30, 2021 7:15am
Karuna investor settles insider trading charges with SEC
May 27, 2021 4:05pm
Roivant's Ramaswamy jumps to executive chair—Chutes & Ladders
Jan 29, 2021 9:30am
